BioTime has contributed to a $10m round for AgeX, an age-related disease treatment developer it has spun out that is now valued at $68m.

Mitsui and corporate venturing units Robert Bosch Venture Capital and Ascension Health Ventures had helped provide $60m to the Aethon, which is set to be acquired by VTLS.

Becton, Dickinson and Company has participated in a round that took the GE Ventures-backed medication analysis technology provider's total funding to $8m.

Anti-aging therapeutics developer Unity Biotechnology has added $35m to a WuXi PharmaTech and Mayo Clinic-backed series B round that it has now closed at $151m.

GlaxoSmithKline-backed Atreca has now raised $91m in total and will use the series B proceeds to advance a pipeline of therapeutics based on human immune responses.

University of Minnesota has revealed it launched 18 spinouts during the past financial year, putting the total number at 119.